Pompe Disease Market - Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2024

The pompe disease market is growing at a significant rate mainly due to special provisions for orphan drugs. Regulatory assistance in emerging nations is one of the major trends seen in the pompe disease market.

Pompe disease is a type of lysergic acid diethylamide (LSD). LSD refers to a group of diseases arising from the increase of specific substrates and is inherited autosomal recessive disorders. Lysergic acid diethylamide is progressive and having uneven age of onset and clinical symptoms. Pompe disease is a hereditary and repeatedly incurable disorder caused by lack of acid alpha glucosidase, an enzyme desired to split down glycogen in particular structures of our body.

Patients having pompe disease have little amount of or no acid alpha glucosidase enzyme activity, so break down of glycogen is not possible. The additional glycogen builds up in the patient and is stored in skeletal muscle, heart and other tissues, which causes the progressive indications of pompe disease. Increase of glycogen in certain organs and tissues restraints normal functions of patient’s organs. Pompe disease is also known by other names such as glycogen storage disease type II, acid maltase deficiency, lysosomal alpha-glucosidase deficiency, acid alpha-glucosidase deficiency and glycogenosis type II.

Request to Get the Sample Pages at:

Pompe disease is categorized into two broad categories as adult-onset pompe disease and infantile onset pompe disease. Both the parents pass on one strangely altered copy of the gene to their child. A parent with an altered copy of the gene is known as a carrier and the disease can affect both men and women irrespective of the gender. The disease is acquired by the individuals at the time of birth only, but the onset of indications differs significantly. The researchers have identified more than 300 genetic mutations that can cause pompe disease. Enzyme replacement therapy and diet therapy are useful in dropping the clinical demonstrations of the disease.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pompe-disease-market

Government regulations, such as orphan drug exclusivity and limited patient population are the factors restraining the growth of the pompe disease market.

Some of the competitors in the market are Genzyme Corporation, EpiVax, Inc., Amicus Therapeutics, Audentes Therapeutics, BioMarin Pharmaceutical Inc., Valerion Therapeutics, LLC, Oxyrane, and Sangamo BioSciences Inc.

Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024

The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth.

Cancer instigates uncountable growth of cells due to some abnormalities in the body. Some of the common symptoms of pancreatic cancer include weight loss, diarrhea, jaundice and abdominal pain. Cancer hampers the pancreas’ normal functioning, with smoking being the major risk factor for pancreatic cancer. Diagnosis of this type of cancer is done by patient history check and complete physical examination, followed by urine, stool and blood tests. Also, personal or family history of pancreatitis and BRCA2 mutation inclines a person to be affected by pancreatic cancer.

Request to Get the Sample Pages at:

In developing countries, improvement in patient-centered care is being encouraged, as governments are investing huge amount of funds. Increasing elderly population base, high prevalence of pancreatic cancer and increase in foreign investments may be observed, over the forecast period, in the developing nations such as Asia-Pacific and Middle East Asia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pancreatic-cancer-therapeutics-market

The investment in both segments of pancreatic cancers is significant. However, the growing prevalence and growing reach of novel techniques in the developing regions are the aspects likely to drive the growth of the exocrine category, throughout the forecast period.

Presently, the global pancreatic cancer therapeutics industry is merged in nature, with only a few top companies seizing the major share of the market. Some of the top companies operating in this market are Celgene Corporation; Eli Lilly and Company; Amgen, Inc.; F. Hoffmann-La Roche AG; PharmaCyte Biotech, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Clovis Oncology; Pfizer, Inc.; and Merck & Co., Inc.

Several companies are concentrating on the introduction of technologically advanced products, in order to obtain a significant share in the fast-growing medical devices area. Also, collaborations, mergers and partnerships with well-established players are the key approaches followed by top players to increase their market share, during the forecast period.

Integrated CDSS Segment Expected to Realize Fastest Growth in the Global CDSS Market, During Forecast Period

The clinical decision support system market size is expected to cross $1.5 billion by 2022, growing at a CAGR of 21.5% between 2016-2022. The CDSS market is driven by five major factors, including growing demand for advanced healthcare information systems, growing investments by HIT players, growing need for remote patient monitoring services, and increasing support from government organizations.

Download report sample at@ https://www.psmarketresearch.com/market-analysis/clinical-decision-support-system-market/report-sample

The massive unexplored CDSS across the globe has created abundant opportunities for the major players to exploit the potential of the CDSS market. Although, there has been significant development in the developed economies of European Union (EU) and the U.S., the clinical decision support system market is still at its nascent form, especially in the developing countries of Asia, Latin America, and Africa. A high growth in numbers of end user including hospitals, and pharmacy has been witnessed in the developing countries of these regions, which provides immense growth opportunities for the CDSS market.

The Asia-Pacific market for CDSS is expected to grow at a CAGR of 23.2% between 2016-2022. The clinical decision support system market in Asia-Pacific is growing, due to growing geriatric population and upsurge in the occurrence rate of different chronic diseases. In addition, the improving healthcare infrastructure, and favorable government support, such as investments and grants has fueled the demand of HIT systems including CDSS in the region. China is expected to grow at a CAGR of 27% during the forecast period and reach $114.3 million by 2022, in the Asia-Pacific CDSS market.

Explore Report at@ https://www.psmarketresearch.com/market-analysis/clinical-decision-support-system-market

Some of the key companies operating in the CDSS market include Cerner Corporation, RELX Group PLC, Epic Systems Corporation, General Electric Company, McKesson Corporation, Zynx Health Incorporated, International Business Machine Corporation, Siemens AG, Allscripts Healthcare Solutions Inc., Meditech and Wolters Kluwer.

GLOBAL CDSS MARKET SEGMENTATION

By Product

• Integrated CDSS Solutions
• Standalone CDSS Solutions

By Application

• Drug Dosing Support
• Clinical Guidelines
• Clinical Reminders
• Drug-Drug Interactions
• Drug Allergy Alerts
• Others

By Model

• Knowledge-based CDSS Solutions
• Non-Knowledge-Based CDSS Solutions

By Mode of Delivery

• On-Premises
• Web-Based
• Cloud-Based

By Component

• Software
• Hardware
• Services

By Healthcare Provider Entity Capacity

• Less than 100 Beds
• 100–199 Beds
• 200–299 Beds
• 300–399 Beds
• 400–499 Beds
• More than 500 Beds

By Region

• North America
• U.S.
• Canada
• Rest of North America
• Western Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Central & Eastern Europe
• Russia
• Rest of Central & Eastern Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East and Africa

Source: P&S Intelligence

Pain Management Drugs Market Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The growing geriatric population and increasing demand of innovative and advanced pain relaxing medications around the world are the predominant growth drivers for the global pain management drugs market. Additionally, the increasing number of hospitalization cases; unmet requirements for neuropathic pain management drugs; innovative and advanced applications of pain management therapies; increasing prevalence of various chronic diseases, such as cancer, and neurological problems; and increasing healthcare expenditure are also driving the growth of the global market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various therapeutic indications, the post-operative pain relief segment accounted for the largest share, and the low-back pain segment accounted for the second largest share in the global market.

Pain management drugs are mainly used to relieve discomfort associated with injury and surgeries. Moreover, pain management medications are used in the management of pain associated with neurological problems, migraine, cancer, orthopedic problems, low- back pain, rheumatoid arthritis, and fibromyalgia.

Request to Get the Sample Pages at: 

North America and Europe are the major markets, due to increasing prevalence of chronic diseases, and growing awareness about various types of chronic pain conditions in these regions. The U.S. followed by Canada, is the largest market for pain management drugs in North America. Whereas, the U.K., Germany and France are some of the major countries holding significant share in the European pain management drugs market.

The Asian market is growing with a significant rate, owing to huge pool of patients, and increasing healthcare spending in the region. In addition, the initiatives taken by various government associations to develop chronic pain rehabilitation centers, and increasing prevalence of various chronic diseases are also supporting the growth of the Asian pain management drugs market. The countries such as India, Japan and China, are the major markets in the region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pain-management-drugs-market

Apart from these regions, Latin America is another important market. This is due to increasing investments by drug manufacturing companies and growing demand of pain management medications in the region. Brazil holds the largest share in the Latin American pain management drugs market, due to the increasing support from government organizations for the development of chronic pain rehabilitation center in the country.

Some of the major players operating in the global pain management drugs market include Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Forest Laboratories Inc., Endo International PLC, Johnson & Johnson, Pfizer Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., and Baxter International Inc.

Pain Management Drugs Market Segmentation

By Category

•              Prescription-Based Drugs

•              Over-The-Counter (OTC) Drugs

By Therapeutic Indications

•              Post-Operative Pain

•              Low-Back Pain

•              Rheumatoid Arthritis Pain

•              Osteoarthritis Pain

•              Cancer Pain

•              Migraine

•              Neuropathic Pain

•              Fibromyalgia

•              Others

By Brands

•              Maxalt

•              Zomig

•              Qutenza

•              Lidoderm

•              Savella

•              Imitrex

•              Voltaren Gel

•              Celebrex

•              Cymbalta

•              Others

By Geography

•              North America

o              U.S.

o              Canada

•              Europe

o              Germany

o              France

o              U.K.

o              Spain

o              Italy

•              Asia

o              Japan

o              China

o              India

•              Latin America

o              Brazil

•              Rest of the World

Neuroendocrine Carcinoma Therapeutics Market Outlook, Growth Opportunities, Major Competitors and Porter Analysis

Global neuroendocrine carcinoma therapeutics market is witnessing significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a tumor that begins in neuroendocrine cells and can spread, or metastasize, to other parts of the body. It starts in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many organs including, lungs, brain and gastrointestinal tract. It is a very rare cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The risk factors of developing neuroendocrine cancer includes, age, gender, family history, immune system suppression, arsenic exposure and sun exposure. The diagnosis can be done by normal physical examination followed by blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.

The treatments available for neuroendocrine tumor include chemotherapy, surgery and radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors. Many pharmaceutical companies have been working continuously for the development of targeted therapy for the growth of neuroendocrine cancer market.

Request to Get the Sample Pages at: 

Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for treatment of neuroendocrine cancer. Genentech Inc., F. Hoffmann-La Roche Ltd., Callisto Pharmaceuticals Pvt. Ltd. and BioSynthema, Inc. are some major companies that are determined to develop therapeutics for various neuroendocrine cancers. Lutathera, Atiprimod and Avastin are pipeline candidates that are presently being studied for their therapeutic efficacy in the treatment of neuroendocrine cancer. Also, there are many other pipeline drugs in Phase III which are expected to enter the neuroendocrine carcinoma therapeutics market in the future.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=neuroendocrine-carcinoma-therapeutics-market

Geographically, neuroendocrine carcinoma therapeutics market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine carcinoma therapeutics market are based in the U.S and therefore consider North America as their main market for product launch and research and development investments. Also, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine carcinoma therapeutics market. Europe is the second largest market for neuroendocrine carcinoma therapeutics, followed by Asia. Increasing prevalence of neuroendocrine cancer in Asia Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Some of the key players operating in the global neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.

Opioid Induced Constipation Market Analysis, Demand, Growth Opportunities and Recent Trends by Leading Manufacturers and Regions

Opioids are directed to the patients suffering from the acute and chronic non-cancer pain. The opioids have numerous adverse intestinal effects, such as opioid-induced constipation. The opioids also affect the discharge of digestive enzymes that can sometime cause partial gastro paresis. Some of the most familiar symptoms of opioid-induced constipation includes, hard and dry stools, swelling, painful defecation, distention and protruded abdomen, tiredness, and loss of hunger. Some of the most common opioid-induced constipation therapy is the use of targeted therapies, OTC and off-label drugs and changing lifestyle.

  

On the basis of different form of drug the global opioid-induced constipation market can be bifurcated into two broad categories: solid and liquid. Some of the dominant market drivers for opioid-induced constipation includes, rising number of OIC patients, and widespread use of opioids treatment in chronic non-cancer pain. The current opioid-induced constipation market is led by the inexpensive and widely available laxatives. The clinical efficiency of laxatives is poor compared to its counterparts; however they still broadly used in constipation relief.

Lack of awareness about the opioid-induced constipation in patients, and the doctors are one of the dominant causes of off-label and OIC medications as majorly used treatment methods. However, the efficiency of these drugs is only the half of some of the other therapies. The entrance of superficially acting mu-opioid receptor rivals such as Movantikv or Moventig are driving the opioid-induced constipation market. Movantikv or Moventig drug targets only the fundamental reason of opioid-induced constipation without affecting the effect of the opioid drugs.

Request to Get the Sample Pages at:

Europe was the largest market of the opioid-induced constipation market in 2015 in terms of value. It is then followed by North America. The market dominance of Europe is attributed the presence of a large number of baby boomers population in the region. North America was the fastest growing market for opioid-induced constipation in 2014, the market size of North America is expected to surpass the Europe during the forecast period. The high growth of the market is attributed to the supportive government incentive in healthcare services in addition with the presence of a large pool of patients suffering from chronic pain.  

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=opioid-induced-constipation-market

In September 2014 the U.S. Food and Drug Administration (FDA) has approved methyl naltrexone bromide hypodermic injection, 12 mg/0.6ml, for the treatment of opioid-induced constipation for the patients using opioids non-cancer chronic pain. This approval from the FDA is expected to serve approx. 11 million patients in the U.S. who are suffering from opioid-induced constipation.

Based on the different form of therapy the global opioid-induced constipation market can be broadly categorized as non-tamper resistant formulations (non-TRFs) and tamper resistant formulations (TRF). The non-TRFs has the largest market share in 2014, however the TRFs is expected to more dominant treatment technology in upcoming years attributed mainly to the U.S. Food and Drug Administration (FDA) promotions and  broad pipeline of oral (TRFs) approval.

Some of the major players operating in the global opioid-induced constipation market include, AstraZeneca plc, Valeant Pharmaceuticals International Inc., Takeda Pharmaceutical Co. Ltd., Salix Pharmaceuticals, Ltd., Progenics Pharmaceuticals, Inc., Abbott Laborites, and Bayer AG among others.

Glaucoma Therapeutics Market Demand, Developments, Industry Opportunities and Industry Research Report

Glaucoma is a disease of eye which is caused by excessive increase of fluid pressure within the eye. Glaucoma is caused due to mechanical compression or decreased blood flow in the optic nerve of the patient’s eye. If not treated properly, it may lead to mild loss of vision and even blindness. Treatment of glaucoma includes laser therapies, pharmaceutical drugs and surgical procedures.

Ocular hypertension is one of the major causes due to which glaucoma occurs in patients. Glaucoma mostly occurs at the age over 40, but it may also occur in children, young adults, and infants. Diagnosis of glaucoma can be done through a simple eye examination with the help of tonometry, an instrument used for measuring intraocular pressure, by an ophthalmologists and optometrist. Prevention of glaucoma is difficult; however, if diagnosed and treated at an early stage, the disease can be controlled by using eye drops prescribed by doctor, microsurgery or by laser surgery. Glaucoma can damage the vision of the affected eye permanently; in first stage it decreases the peripheral vision and if not treated, it can lead to blindness.

Request to Get the Sample Pages at:

Some of the major factors driving the growth of glaucoma therapeutics market are aging population of developed countries, development of advanced glaucoma drug delivery devices and rising global healthcare expenditures. Stringent government regulation and marketing approval, side effects of glaucoma medications and long development process of the glaucoma products are some of the major factors restraining the growth of global glaucoma therapeutics market.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=glaucoma-therapeutics-market

North America was the largest glaucoma therapeutics market in 2014, attributed to high per capita expenditure on healthcare in this region. It is followed by Europe and Asia-Pacific. Asia-Pacific region is also the fastest growing glaucoma therapeutics market, owing to the aging population of Japan coupled with the increasing healthcare expenditure of developing countries, such as India and China. Asia-Pacific glaucoma therapeutics market is further expected to witness growth and surpass North America market in terms of largest market during the coming years.

Some of the major competitors in global glaucoma therapeutics market are Pfizer Inc., Allergen Inc., Novartis A.G., Merck & Co. Inc., Aerie Pharmaceuticals Inc., Inotek Pharmaceuticals Corp., Carl Zeiss Meditec Inc., Acadia Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., NicOx SA, Santen Pharmaceuticals Co. Ltd., Otsuka Holdings Co. Ltd., SIFI SpA, and Valeant Pharmaceuticals International Inc.

Testicular Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand

Global testicular cancer therapeutics market is growing with the increasing prevalence of testicular cancer. The market is expected to witness moderate growth, since there are already more than 15 drugs that exist in the market for the treatment of testicular cancer. Increasing prevalence of cancer and rising demand for the medications with better efficacy and less side effects can be attributed as an opportunity for oncology. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process. 

Testicular cancer is the tumor that develops in the testicles. Testicles are the glands found in men that produce testosterone hormone and sperms. The cause of testicular cancer is attributable to enormous growth of testicular cells due to some abnormalities, resulting in the formation of tumor in testicles, causing testicular cancer. Cryptorchidism, inguinal hernia, congenital abnormalities, abnormal testicular development and family history can increase the risk of testicular cancer. Mumps orchitis are also one of risk factors which is a very rare complication of mumps, which involves the inflammation of testicles. Pain, swelling, discomfort, sensation of heaviness and sudden fluid accumulation in scrotum are the main symptoms of testicular cancer.

Request to Get the Sample Pages at: 

Growing prevalence of testicular cancer and combination therapies for the treatment are the major driving forces for the testicular cancer therapeutics market. Also with no drug in Phase III, there is a need for growth in pipeline for better treatment options, providing increased opportunities to the players in the market. Some of the marketed drugs for the treatment of testicular cancer include Blenoxane (Bleomycin), Cisplatin, Cosmegen (Dactinomycin), Cyfos (Ifosfamide), Etopophos (Etoposide Phosphate) and Velban (Vinblastine Sulfate). Some of the drug combination available in the market are BEP, JEB, PEB, VIP and VeIP.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=testicular-cancer-therapeutics-market

The treatment is more effective if the chemotherapy regimen involves two or more drugs rather than using any single drug. Therefore, chemotherapy is expected to have major share in the global testicular cancer therapeutics market.

Some of the key players operating in the global testicular cancer therapeutics market are Ovation Pharmaceuticals, Inc., ZIOPHARM Oncology Inc., Bristol-Myers Squibb Company, Hospira Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG and Teva Parenteral Medicines, Inc.